Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation

Pain

Volumn 76, Issue 1-2, 1998, Pages 27-33

  Eckhardt, Klaus ^a   Li, Shuxia ^a   Ammon, Susanne ^a   Schänzle, Gerhard ^a   Mikus, Gerd ^a   Eichelbaum, Michel ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

Analgesic effect; Codeine; Cold pressor test; CYP2D6; Morphine; Pharmacokinetics; Side effect

Indexed keywords

CODEINE; CYTOCHROME P450; DRUG METABOLIZING ENZYME; MORPHINE;

ADULT; ANALGESIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG METABOLISM; DYSPHORIA; FEMALE; FLUSHING; GENETIC POLYMORPHISM; HEADACHE; HUMAN; MALE; NAUSEA; PAIN THRESHOLD; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEDATION; VERTIGO; VISUAL IMPAIRMENT;

ADULT; ANALGESICS, OPIOID; AREA UNDER CURVE; CODEINE; CYTOCHROME P-450 CYP2D6; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HUMANS; MALE; MORPHINE; PAIN MEASUREMENT; PHENOTYPE;

EID: 0031746749     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(98)00021-9     Document Type: Article

References (31)

1. Adler T.K., Fujimoto J.M., Way E.L., Baker E.M. The metabolic fate of codeine in man. J. Pharmacol. Exp. Ther. 114:1955;251-262.
2. Arkinstall W., Sandler A., Goughnour B., Babul N., Harsanyi Z., Darke A.C. Efficacy of controlled-release codeine in chronic non malignant pain: a randomized, placebo controlled clinical trial. Pain. 62:1995;169-178.
3. Caraco Y., Sheller J., Alastair J., Wood J. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. J. Pharmacol Exp. Ther. 278:1996;1165-1174.
4. Chen Z.R., Somogyi A.A., Bochner F. Polymorphic O-demethylation of codeine. Lancet. 2:1988;914-915.
5. Chen, Z.R., Somogyi, A.A., Reynolds, G. and Bochner, F., Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers, Br. J. Clin. Pharmacol., 31 (1991a) 381-390.
6. Chen, Z.R., Irvine, R.J., Somogyi, A.A. and Bochner F., Mu receptor binding of some commonly used opioids and their metabolites, Life Sci., 48 (1991b) 2165-2171.
7. Daly A.K., Brockmöller J., Broly F., Eichelbaum M., Evans W.E., Gonzalez F.J., Huang J.-D., Idle J.R., Ingelman-Sundberg M., Ishizaki T., Jacqz-Aigrain E., Meyer U.A., Nebert D.W., Steen V.M., Wolf C.R., Zanger U.M. Nomenclature for human CYP2D6 alleles. Pharmacogenetics. 6:1996;193-201.
8. Dayer P., Desmeules J., Leemann T., Striberni R. Bioactivation of narcotic drug codeine is mediated by the polymorphic monoxygenase catalysing debrisoquin 4-hydroxylation. Biochem. Biophys. Res. Commun. 152:1988;411-416.
9. Desmeules J., Gascon M.P., Dayer P., Magistris M. Impact of environmental and genetic factors on codeine analgesia. Eur. J. Clin. Pharmacol. 41:1991;23-26.
10. Eggen A.E., Andrew M. Use of codeine analgesics in a general population. A Norwegian study of moderately strong analgesics. Eur. J. Clin. Pharmacol. 46:1994;491-496.
11. Eichelbaum M., Gross A. The genetic polymorphism of debrisoquine/sparteine metabolism: clinical aspects. Pharmacol. Ther. 46:1990;377-394.
12. Garcia de Jalon P.D., Harrison F.J.J., Johnson K.I., Kozma C., Schnelle K. A modified cold stimulation technique for the evaluation of analgesic activity in human volunteers. Pain. 22:1985;183-189.
13. Gourlay G.K., Willis R.J., Lamberty J. A double-blind comparison of the efficacy of methadone and morphine in postoperative pain control. Anesthesiology. 64:1986;322-327.
14. Hennies H.H., Friderichs E., Schneider J. Receptor binding, analgesic effect and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung. 38:1988;877-880.
15. Hofmann U., Fromm M.F., Johnson S., Mikus G. Simultaneous determination of dihydrocodeine and dihydromorphine in serum by gas chromatography-tandem mass spectrometry. J. Chromatogr. B. 663:1995;59-65.
16. Honig S. nad Murray, K.A., An appraisal of codeine as an analgesic. J. Clin. Pharmacol. 24:1984;96-102.
17. Jochimsen P.R., Noyes R. Appraisal of codeine as an analgesic in older patients. J. Am. Geriat. Soc. 26:1978;521-523.
18. Jones S.F., McQuay H.J., Moore R.A., Hand C.W. Morphine and ibuprofen compared using the cold pressor test. Pain. 34:1988;117.
19. Mikus G., Trausch B., Rodewald C., Hofmann U., Richter K., Gramatte T., Eichelbaum M. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. Clin. Pharmacol. Ther. 61:1997;459-465.
20. 3H] GBR-12935 binding proteins. Arch. Biochem. Biophys. 276:1990;424-432.
21. Oldendorf W.H., Hyman S., Braun L., Oldendorf S.Z. Blood-brain barrier: penetration of morphine, codeine, heroin and methadone after carotid injection. Science. 178:1972;984-986.
22. Plummer J.L., Cmielewski P.L., Reynolds G.D., Gourlay G.K., Cherry D.A. Influence of polarity on dose-response relationships of intrathecal opioids in rats. Pain. 50:1990;339-347.
23. Poulsen L., Brosen K., Arendt-Nielsen L., Gram L.F., Elbaek K., Sindrup S.H. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur. J. Clin. Pharmacol. 51:1996;289-295.
24. Sindrup S.H., Brosen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics. 5:1995;335-346.
25. Sindrup S.H., Arendt-Nielsen L., Brosen K., Bjerring P., Angelo H.R., Eriksen B., Gram L.F. The effect of quinidine on the analgesic effect of codeine. Br. J. Clin. Pharmacol. 42:1989;587-592.
26. Sindrup S.H., Brosen K., Bjerring P., Arendt-Nielsen L., Larsen U., Angelo H.R., Gram L.F. Codeine increases pain threshold to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin. Pharmacol. Ther. 49:1991;686-693.
27. Sindrup S.H., Poulsen L., Brosen K., Arendt-Nielsen L., Gram L.F. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers? Pain. 53:1993;335-349.
28. Sindrup S.H., Hofmann U., Asmussen J., Mikus G., Brosen K., Nielsen F., Ingwersen S.H., Christensen C.B. Impact of quinidine on plasma and spinal fluid concentrations of codeine and morphine after codeine intake. Eur. J. Clin. Pharmacol. 49:1996;503-509.
29. Tyndale R.F., Sunahara R., Inaba T., Kalow W., Gonzales F.J., Niznik H.B. Neuronal cytochrome P450IID 1 (debrisoquine/sparteine-type): potent inhibition of activation by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol. Pharmacol. 40:1991;63-68.
30. Yue Q.Y., Svensson J.O., Alm C., Sjöqvist F., Säwe K. Codeine O-demethylation cosegregates with polymorphic debrisoquine hydroxylation. Br. J. Clin. Pharmacol. 28:1989;639-645.
31. Yue Q.Y., Hasselström J., Svensson J.O., Säwe K. Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. Br. J. Clin. Pharmacol. 31:1991;635-642.